SCHEMBL2979620

SCHEMBL2979620

[CH2]NC(=O)c1ccc(N2CCCC2)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2T Q9NPD8 1/20 0.56
ALDH1A1 P00352 7/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
HPGD P15428 3/20 0.55
HPGDS O60760 2/20 0.53
KCNQ3 O43525 1/20 0.52
KCNQ2 O43526 1/20 0.52
KDM4E B2RXH2 2/20 0.51
POLB P06746 1/20 0.51
ALOX15 P16050 1/20 0.51
HSD17B10 Q99714 1/20 0.51
MCHR1 Q99705 1/20 0.48
TRPV1 Q8NER1 1/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
KMT2A Q03164 1/20 0.47
HDAC6 Q9UBN7 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 3/20 0.45
AOC3 Q16853 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2570318 0.87 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2HPGDHPGDSKCNQ3
SCHEMBL30175325 0.84 UBE2T (0.56) UBE2TALDH1A1SMN1; SMN2HPGDHPGDS
SCHEMBL3598305 0.84 UBE2T (0.60) UBE2TALDH1A1SMN1; SMN2HPGDHPGDS
SCHEMBL7325011 0.83 ALDH1A1 (0.60) UBE2TALDH1A1SMN1; SMN2HPGDHPGDS
SCHEMBL1989630 0.80 UBE2T (0.63) UBE2TALDH1A1SMN1; SMN2HPGDHPGDS
SCHEMBL29784322 0.80 UBE2T (0.63) UBE2TALDH1A1SMN1; SMN2HPGDHPGDS
SCHEMBL23929985 0.79 UBE2T (0.61) UBE2TALDH1A1SMN1; SMN2HPGDHPGDS
SCHEMBL184277 0.79 UBE2T (0.61) UBE2TALDH1A1SMN1; SMN2HPGDHPGDS
SCHEMBL4850532 0.79 UBE2T (0.61) UBE2TALDH1A1SMN1; SMN2HPGDHPGDS
SCHEMBL30175332 0.79 UBE2T (0.61) UBE2TALDH1A1SMN1; SMN2HPGDHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2057115-B9 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC (US) 2012-12-26 EP claimed
EP-2057115-B1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC (US) 2012-10-03 EP claimed
US-8183289-B2 4-substituted phenoxyphenylacetic acid derivatives ARRAY BIOPHARMA INC. (US) 2012-05-22 US claimed
US-20100173955-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2010-07-08 US claimed
US-8492437-B2 4-substituted phenoxyphenylacetic acid derivatives ARRAY BIOPHARMA INC. (US) 2013-07-23 US disclosed
EP-2057115-B9 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC (US) 2012-12-26 EP disclosed
EP-2057115-B1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC (US) 2012-10-03 EP disclosed
US-20120202854-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2012-08-09 US disclosed
US-8183289-B2 4-substituted phenoxyphenylacetic acid derivatives ARRAY BIOPHARMA INC. (US) 2012-05-22 US disclosed
US-20100173955-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173955-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES CD22, HRH2, CD74 UBE2T 1057/4885ALDH1A1 610/4885SMN1; SMN2 3361/4885
US-20120202854-A1 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES CD22, HRH2, CD74 UBE2T 1057/4885ALDH1A1 610/4885SMN1; SMN2 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.